Last reviewed · How we verify
Polyoxidonium
Polyoxidonium is a Small molecule drug developed by NPO Petrovax. It is currently in Phase 2 development. Also known as: azoximer bromide.
Polyoxidonium, also known as Azoximer bromide, is a small molecule immunomodulator used as an adjuvant in influenza vaccines such as Grippol Quadri and Grippol Plus. It has been studied in clinical trials for conditions including influenza, acute respiratory infection, infections, and coronavirus.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Polyoxidonium |
|---|---|
| Also known as | azoximer bromide |
| Sponsor | NPO Petrovax |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers (PHASE2, PHASE3)
- Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19 (PHASE2, PHASE3)
- Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19
- Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyoxidonium CI brief — competitive landscape report
- Polyoxidonium updates RSS · CI watch RSS
- NPO Petrovax portfolio CI
Frequently asked questions about Polyoxidonium
What is Polyoxidonium?
Who makes Polyoxidonium?
Is Polyoxidonium also known as anything else?
What development phase is Polyoxidonium in?
Related
- Manufacturer: NPO Petrovax — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: azoximer bromide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing